Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primaquine with artemether-lumefantrine and tafenoquine with sulfadoxine-pyrimethamine plus amodiaquine for malaria transmission blocking in Mali
NL-OMON23822Active, not recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Oct 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of primaquine, tafenoquine, artemether, lumefantrine, sulfadoxine and 2 more in malaria (4 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Change in mosquito infection rate assessed through membrane feeding assays. Started Oct 2021; status: active, not recruiting.
02
Drugs
primaquinetafenoquineartemetherlumefantrinesulfadoxine
03
Conditions
malaria
Beyond the preview
Go deeper on NL-OMON23822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23822.